Profile
| Metric | Value |
|---|---|
| Full Name | Amgen Inc. |
| Ticker | NASDAQ: AMGN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | amgen.com |
| Employees | 28,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $326.10 | |
| Price, 1D Change | -1.21% | |
| Market Cap | $176B | |
| TTM Dividend Yield | 2.92% | |
| PE Ratio | 25.21 | |
| Beta | 0.42 | |
| Revenue | $33B | |
| Revenue, 1Y Change | +18.64% | |
| EPS | $7.56 | |
| EPS, 1Y Change | -39.45% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $2.38 | |
| Next Ex-Dividend | $2.52 | |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $7.56 | |
| EPS Estimate | $21.27 | |
| EPS Est. Change | +181.33% | |
| Revenue | $33.23B | |
| Revenue Estimate | $36.32B | |
| Revenue Est. Change | +9.29% | |
| Current Price | $326.10 | |
| Price Target | - | $325.00 |
| Price Tgt. Change | - | -0.34% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $18.56 | $12.49 | -32.73% | |
| $19.60 | $7.56 | -61.43% | |
| $21.27 | N/A | +181.33% | |
| $21.95 | N/A | +190.37% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $28.15B | $28.01B | -0.50% | |
| $33.19B | $33.23B | +0.13% | |
| $36.32B | N/A | +9.29% | |
| $36.91B | N/A | +11.07% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +23.42% | |
| Price, 3Y | +20.72% | |
| Market Cap, 1Y | +23.76% | |
| Market Cap, 3Y | +21.74% | |
| Revenue, 1Y | +18.64% | |
| Revenue, 3Y | +27.88% | |
| EPS, 1Y | -39.45% | |
| EPS, 3Y | -26.49% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $326.10 | |
| SMA 200 | $298.16 | |
| SMA 200 vs Price | -8.57% | |
| SMA 50 | $327.35 | |
| SMA 50 vs Price | +0.38% | |
| Beta | 0.42 | |
| ATR | $7.41 | |
| 14-Day RSI | 48.21 | |
| 10-Day Volatility | 33.00% | |
| 1-Year Volatility | 28.10% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $2.38 | |
| Upcoming | $2.52 | |
| Dividend Yield | 2.76% | |
| Total Dividend | $9.00 | |
| Dividends Paid | $4.83B | |
| Payout Ratio | 118.14% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $33.23B | |
| EPS | $7.56 | |
| Gross Profit | $20.57B | |
| Gross Margin | 64.19% | |
| Operating Profit | $7.26B | |
| Operating Margin | 21.71% | |
| Net Income | $4.09B | |
| Net Margin | 12.24% | |
| EBITDA | $7.76B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 10.23 | |
| Current Ratio | 1.26 | |
| Quick Ratio | 0.95 | |
| - | ||
| F-Score | 7 | |
| Altman Z-Score | 1.52 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 25.21 | |
| PS Ratio | 4.89 | |
| PB Ratio | 18.26 | |
| EV/EBITDA | 14.08 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $5.88B | |
| Cash & Equivalents | $11.97B | |
| Total Assets | $91.84B | |
| Current Assets | $29.03B | |
| Total Liabilities | $85.96B | |
| Current Liabilities | $23.10B | |
| Total Debt | $60.88B | |
| Short Term Debt | $3.66B | |
| Accounts Payable | $1.91B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $26.17B | |
| Operating Expenses | $13.31B | |
| Cost Of Goods Sold | $12.86B | |
| SG&A | $7.10B | |
| D&A | $5.59B | |
| Interest Expense | $0.00 | |
| Income Tax | $519.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $11.49B | |
| CFI | -$1.05B | |
| CFF | -$9.42B | |
| Capex | $1.10B | |
| Free Cash Flow | $10.39B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| Wells Fargo | → | |
| BMO Capital | → | |
| Piper Sandler | → | |
| Cantor Fitzgerald | → | |
| Wells Fargo | → | |
| Morgan Stanley | → | |
| B of A Securities | → | |
| Piper Sandler | → | |
| UBS | → |
Analyst sentiment
Institutional ownership
Screeners with AMGN
Data Sources & References
- AMGN Official Website www.amgen.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- List of Dow Jones Industrial Average Companies en.wikipedia.org/wiki/Dow_Jones_Industrial_Average
- AMGN Profile on Yahoo Finance finance.yahoo.com/quote/AMGN
- AMGN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/amgn
FAQ
What is the ticker symbol for Amgen Inc.?
The ticker symbol for Amgen Inc. is NASDAQ:AMGN
Does Amgen Inc. pay dividends?
Yes, Amgen Inc. pays dividends. The last payment was $2.38, with an ex-dividend date on November 21, 2025
What sector is Amgen Inc. in?
Amgen Inc. is in the Healthcare sector
What industry is Amgen Inc. in?
Amgen Inc. is in the General Drug Manufacturers industry
What country is Amgen Inc. based in?
Amgen Inc. is headquartered in United States
When did Amgen Inc. go public?
Amgen Inc. initial public offering (IPO) was on June 17, 1983
Is Amgen Inc. in the S&P 500?
Yes, Amgen Inc. is included in the S&P 500 index
Is Amgen Inc. in the NASDAQ 100?
Yes, Amgen Inc. is included in the NASDAQ 100 index
Is Amgen Inc. in the Dow Jones?
Yes, Amgen Inc. is included in the Dow Jones index
When was Amgen Inc. last earnings report?
Amgen Inc.'s most recent earnings report was on November 4, 2025
When does Amgen Inc. report earnings?
The next expected earnings date for Amgen Inc. is February 3, 2026
